New drug tested in fight against deadly sepsis kidney damage
NCT ID NCT05507437
Summary
This study tested an experimental drug called TIN816 in hospitalized patients whose kidneys were injured by a severe bloodstream infection (sepsis). The main goals were to see how the drug moves through the body, if it is safe, and how well it is tolerated. Twenty critically ill adults in intensive care received either the drug or a placebo, and researchers monitored them for 90 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY DUE TO SEPSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Genk, 3600, Belgium
-
Novartis Investigative Site
Ottignies, 1340, Belgium
-
Novartis Investigative Site
Strasbourg, 67091, France
-
Novartis Investigative Site
Toulouse, 31054, France
-
Novartis Investigative Site
Kiel, 24105, Germany
-
Novartis Investigative Site
Debrecen, 4032, Hungary
-
Novartis Investigative Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.